GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-Biologics Inc (XKRX:338840) » Definitions » COGS-to-Revenue

Y-Biologics (XKRX:338840) COGS-to-Revenue : 0.36 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Y-Biologics COGS-to-Revenue?

Y-Biologics's Cost of Goods Sold for the three months ended in Mar. 2024 was ₩407 Mil. Its Revenue for the three months ended in Mar. 2024 was ₩1,143 Mil.

Y-Biologics's COGS to Revenue for the three months ended in Mar. 2024 was 0.36.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Y-Biologics's Gross Margin % for the three months ended in Mar. 2024 was 64.38%.


Y-Biologics COGS-to-Revenue Historical Data

The historical data trend for Y-Biologics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Y-Biologics COGS-to-Revenue Chart

Y-Biologics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
COGS-to-Revenue
Get a 7-Day Free Trial 0.70 0.59 0.15 0.51 0.68

Y-Biologics Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only 0.61 0.37 0.14 0.24 0.36

Y-Biologics COGS-to-Revenue Calculation

Y-Biologics's COGS to Revenue for the fiscal year that ended in Dec. 2022 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=2814.101 / 4150.558
=0.68

Y-Biologics's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=406.984 / 1142.665
=0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Y-Biologics  (XKRX:338840) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Y-Biologics's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 406.984 / 1142.665
=64.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Y-Biologics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Y-Biologics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Y-Biologics (XKRX:338840) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
No. 715, 17, Tech-ro 4-ro, Yuseong-gu, Daejeon, KOR
Y-Biologics Inc is a company has a variety of development candidate antibodies based on Korea's highest-level antibody discovery platform technology and then independently develops antibody treatments or jointly develops cutting-edge biopharmaceuticals by fusing them with our partner's platform technology. Its main business model is based on a globally competitive antibody discovery platform and consists of development of new bio drug candidates and early technology transfer, and contract research services that generate stable cash flow.

Y-Biologics (XKRX:338840) Headlines

No Headlines